China’s Metformin HCL market witnessed strong upward momentum throughout April 2026 as tightening spot availability and robust domestic and export demand supported higher quotations. Regulatory audits in Hebei and Shandong reduced operating rates at several API plants, while large coastal producers prioritized long-term contract volumes, limiting spot cargo availability. At the same time, pharmaceutical manufacturers and hospital procurement programs maintained steady purchasing activity, while increased buying interest from India, Brazil, and Russia intensified competition for export cargoes. Rising feedstock and energy costs further strengthened the bullish market sentiment. Higher natural gas, LNG, dimethylamine, and dicyandiamide costs increased overall production expenses, while Middle East geopolitical tensions disrupted raw material flows and raised freight and marine insurance charges. Reduced inventories at Shanghai warehouses also tightened market availability and supported stronger offers. During the first half of May, Metformin HCL prices remained firm amid continued cost inflation and sustained export demand. Looking ahead, the market could witness further upward movement in the second half of May if feedstock pressures, supply tightness, and export enquiries continue to persist.
China’s Metformin HCL market recorded a strong upward trend throughout April 2026 as tightening spot availability and sustained domestic and export demand pushed Metformin HCL suppliers to raise quotations. Market participants reported that regulatory audits during early April reduced operating rates at several mid-sized API facilities in Hebei and Shandong, limiting the availability of spot cargoes. At the same time, large coastal manufacturers operated at high utilization levels to fulfil long-term contractual commitments, reducing spare export volumes in the Metformin HCL market. During the first half of May, Metformin HCL prices remained firm as rising feedstock costs and continued export demand supported bullish market sentiment. Market participants also noted that higher prices of key raw materials, including dicyandiamide and dimethylamine hydrochloride, further increased production costs and reinforced stronger supplier offers. Looking ahead to the second half of May, the Metformin HCL market could witness additional price increases if current supply tightness and cost pressures persist.
Demand conditions remained supportive for Metformin HCL across both domestic and overseas markets. Pharmaceutical manufacturers, including API and finished-dose producers, maintained active procurement throughout April, while hospital tender cycles continued to ensure stable baseline consumption. According to ChemAnalyst, India’s finished-dose manufacturers accelerated purchasing activity during the month, while export demand of Metformin HCL from Brazil and Russia also expanded steadily. The increase in overseas enquiries intensified competition for Metformin HCL FOB Shanghai cargoes and enabled suppliers to secure higher offers.
Supply-side pressures further strengthened the bullish momentum in the Metformin HCL market. Rising production costs associated with higher natural gas and LNG prices increased ammonia and methanol feedstock expenses, while elevated dimethylamine synthesis costs pushed conversion expenses higher across the Metformin HCL supply chain. Industry participants also noted that Middle East geopolitical tensions disrupted Gulf feedstock flows and increased marine insurance premiums and freight costs, contributing to longer replenishment lead times and higher delivered raw material costs.
In addition, inventories of Metformin HCL at Shanghai warehouses declined significantly during April as export shipments increased and domestic procurement remained firm. Producers reported that limited spot cargo availability and lower warehouse stocks supported aggressive offer revisions throughout the month. Market sentiment also strengthened as European Metformin HCL buyers redirected procurement towards Chinese suppliers amid maintenance shutdowns at regional facilities, tightening export availability further.
During the first half of May, Metformin HCL prices remained firm amid continued feedstock inflation and elevated production expenses. Market participants stated that higher crude oil and natural gas prices increased operating costs, while rising prices of dicyandiamide and dimethylamine hydrochloride further raised Metformin HCL manufacturing expenses. Disruptions around the Strait of Hormuz also increased freight and raw material shipping costs, reinforcing bullish sentiment in the Metformin HCL market. Export demand remained healthy during the period, supporting continued strength in trading activity.
Looking ahead to the second half of May, the Metformin HCL market could witness additional price increases if current supply tightness and feedstock pressures persist. ChemAnalyst expects Metformin HCL prices to remain supported by reduced export availability, lower Shanghai inventories, and sustained procurement from overseas finished-dose manufacturers and hospital tenders. However, any easing in feedstock costs or normalization of overseas supply conditions could moderate the pace of price increases in the coming months.
